- Home
- LSTA vs CGTX Comparison
LSTA vs CGTX Comparison
Compare LSTA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSTA | CGTX |
|---|---|---|
| Founded | 1980 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LSTA | CGTX |
|---|---|---|
| Price | $2.06 | $1.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $23.50 | $2.88 |
| AVG Volume (30 Days) | 22.0K | ★ 938.2K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $0.22 |
| 52 Week High | $4.20 | $3.83 |
Technical Indicators
Market Signals| Indicator | LSTA | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.84 | 46.12 |
| Support Level | $1.96 | $1.46 |
| Resistance Level | $2.10 | $1.61 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 67.74 | 27.03 |
Price Performance
Historical ComparisonAbout LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.